Insulin-like growth factor-I and prostate cancer: A meta-analysis

British Journal of Cancer

Volumn 85, Issue 7, 2001, Pages 991-996

  Shi, R ^a   Berkel, H J ^a   Yu, H ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Case control studies; IGF I; Meta analysis; Odds ratio; Prostate cancer

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CLINICAL TRIAL; HORMONE BLOOD LEVEL; HUMAN; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

ADULT; AGED; CASE-CONTROL STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; ODDS RATIO; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0035964587     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6691961     Document Type: Article

References (27)

1. Low serum insulin-like growth factor I (IGF-I): A significant association with prostate cancer
2. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
3. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
4. Some statistical issues in psychological research
5. Meta-analysis in clinical trials
6. Insulin-like growth factor I (IGF-I), IGF-I density, and IGF-I/PSA ratio for prostate cancer detection
7. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen
8. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
9. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3 and prostate-specific antigen as predictors of clinical prostate cancer
10. Fixed effects models
11. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostate hyperplasia
12. Insulin-like growth factors and their binding proteins: Biological actions
13. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index
14. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body, mass index, and pubertal maturation
15. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen
16. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer
17. The significance of serum levels of insulin-like growth factor-I in patients with prostate cancer
18. Insulin-like growth factor I in relation to prostate cancer and benign prostatic hyperplasia
19. On the epidemiology of oral contraceptives and disease
20. A simple general purpose display of magnitude of experimental effect
21. Parametric measures of effect size
22. Insulin-like growth factor-binding protein-I and prostate cancer
23. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study
24. Insulin-like growth factor I and prostate cancer risk: A population-based, case-control study